The Appearance of Pulmonary Mucormycosis on FDG PET/CT

Dang, Chun-Jiang; Li, Yajun; Zhan, Feng-Hua; Shang, Xiao-ming

doi:10.1097/rlu.0b013e31825ae470

Cited by 13 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a report, Dang et al described their FDG-PET/CT findings in a case of pulmonary mucormycosis as prominent peripheral uptake in a heterogeneous soft tissue mass 74 . Recent studies have also begun to recognize increased rhino-orbital mucormycosis susceptibility in patients with moderate to severe COVID-19 infection 75 .…”

Section: Mucormycosismentioning

confidence: 99%

FDG-PET/CT of COVID-19 and Other Lung Infections

Eibschutz

Rabiee

Asadollahi

et al. 2022

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

While not conventionally used as the first-line modality, [ 18 F]-2-fluoro-2-deoxy-D-glucose (FDG) - positron emission tomography/computed tomography (PET/CT) can identify infection and inflammation both earlier and with higher sensitivity than anatomic imaging modalities [including chest X-ray (CXR), computed tomography (CT), and magnetic resonance imaging (MRI)]. The extent of inflammation and, conversely, recovery within the lungs, can be roughly quantified on FDG-PET/CT using maximum standardized uptake value (SUVmax) values. The Coronavirus disease 2019 (COVID-19) pandemic has highlighted the value of FDG-PET/CT in diagnosis, elucidation of acute pulmonary and extra-pulmonary manifestations, and long-term follow up. Similarly, many other pulmonary infections such as previously documented coronaviruses, Aspergillosis, Blastomycosis, Candidiasis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucormycosis, and typical/atypical Mycobacterial infections have all been identified and characterized using FDG-PET/CT imaging. The goal of this review is to summarize the actual and potential benefits of FDG-PET/CT in the imaging of COVID-19 and other lung infections. Further research is necessary to determine the best indications and clinical applications of FDG-PET/CT, improve its specificity, and ultimately ascertain how this modality can best be utilized in the diagnostic work up of infectious pathologies.

show abstract

Section: Mucormycosismentioning

confidence: 99%

FDG-PET/CT of COVID-19 and Other Lung Infections

Eibschutz

Rabiee

Asadollahi

et al. 2022

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…In addition to anatomic imaging modalities, functional and metabolic imaging using (PET/CT) coupled with [18F]-fluorodeoxyglucose (FDG) has been considered a valuable tool in the diagnosis and management of mucormycosis. Several reports have demonstrated an increased FDG uptake at the site of lesion upon diagnosis with FDG PET/CT during mucormycosis, and after antifungal therapy, the FDG uptake was reduced at the infection site (Dang et al 2012 ; Liu et al 2013 ; G Díaz et al 2019 ; Song 2019 ; Gallo et al 2019 ). Currently there are no reports supporting use of any particular technique in diagnosis of CAM.…”

Section: Rapid Detection Of Mucormycosismentioning

confidence: 99%

COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis

Samson

Dharne

2021

3 Biotech

View full text Add to dashboard Cite

The post-coronavirus disease (COVID-19) mucormycosis is a deadly addition to the pandemic spectrum. Although it’s a rare, aggressive, and opportunistic disease, the associated morbidity and mortality are significant. The complex interplay of factors aggravating CAM is uncontrolled diabetes, irrational and excessive use of antibiotics, steroids, and an impaired immune system. Recently, India has been witnessing a rapid surge in the cases of coronavirus disease-associated mucormycosis (CAM), since the second wave of COVID-19. The devastating and lethal implications of CAM had now become a matter of global attention. A delayed diagnosis is often associated with a poor prognosis. Therefore, the rapid and early diagnosis of infection would be life-saving. Prevention and effective management of mucormycosis depend upon its early and accurate diagnosis followed by a multimodal therapeutic approach. The current review summarizes an array of detection methods and highlights certain evolving technologies for early and rapid diagnosis of CAM. Furthermore, several potential management strategies have also been discussed, which would aid in tackling the neglected yet fatal crisis of mucormycosis associated with COVID-19.

show abstract

“…[10] These lesions are positive on FDG PET as they contains activated inflammatory cells and granulation tissue [Figure 5]. [11]…”

Section: Mucormycosismentioning

confidence: 99%

Lung masses of unusual histologies mimicking malignancy: Flurodeoxyglucose positron emission tomography-computed tomography appearance

et al. 2019

View full text Add to dashboard Cite

18F flurodeoxyglucose positron emission tomography-computed tomography (18F FDG PET-CT) is widely used in the evaluation of patients with lung mass suspicious for malignancy. In addition to malignancy, a variety of benign neoplasms and inflammatory lesions can arise in the lungs, many of which show increased FDG concentration, thereby mimicking malignancy. Awareness of the common mimics of lung cancer and a thorough understanding of their key imaging characteristics on CT as well as FDG PET is helpful in narrowing the differential diagnosis, eventually leading to appropriate therapy. In this article, we enlist these mimics and discuss their metabolic and morphologic characteristics and provide a pathophysiological basis for their FDG uptake.

show abstract

The Appearance of Pulmonary Mucormycosis on FDG PET/CT

Cited by 13 publications

References 7 publications

FDG-PET/CT of COVID-19 and Other Lung Infections

FDG-PET/CT of COVID-19 and Other Lung Infections

COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis

Lung masses of unusual histologies mimicking malignancy: Flurodeoxyglucose positron emission tomography-computed tomography appearance

Contact Info

Product

Resources

About